EP0000533A1 - N-Substituted 9,10-dihydrolysergic acid esters and a method for their preparation - Google Patents
N-Substituted 9,10-dihydrolysergic acid esters and a method for their preparation Download PDFInfo
- Publication number
- EP0000533A1 EP0000533A1 EP78100419A EP78100419A EP0000533A1 EP 0000533 A1 EP0000533 A1 EP 0000533A1 EP 78100419 A EP78100419 A EP 78100419A EP 78100419 A EP78100419 A EP 78100419A EP 0000533 A1 EP0000533 A1 EP 0000533A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydrogen
- atoms
- compound
- general formula
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- ORBSYPFBZQJNJE-MPKXVKKWSA-N (6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carboxylic acid Chemical class C1=CC([C@H]2C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ORBSYPFBZQJNJE-MPKXVKKWSA-N 0.000 title claims description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 18
- 239000001257 hydrogen Substances 0.000 claims abstract description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 17
- 239000008346 aqueous phase Substances 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 11
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
- 150000002367 halogens Chemical class 0.000 claims abstract description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 6
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- 150000007513 acids Chemical class 0.000 claims abstract description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 239000003960 organic solvent Substances 0.000 claims abstract description 4
- 239000003444 phase transfer catalyst Substances 0.000 claims abstract description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 15
- 238000006243 chemical reaction Methods 0.000 abstract description 14
- 150000002148 esters Chemical class 0.000 abstract description 9
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 239000000543 intermediate Substances 0.000 abstract description 5
- 239000002904 solvent Substances 0.000 abstract description 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 18
- 239000012071 phase Substances 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 5
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000012485 toluene extract Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 2
- 229940008406 diethyl sulfate Drugs 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- -1 phosphonium compound Chemical class 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- FQIUCPGDKPXSLL-UHFFFAOYSA-N 5-bromopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(Br)=C1 FQIUCPGDKPXSLL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- RKHXQBLJXBGEKF-UHFFFAOYSA-M tetrabutylphosphanium;bromide Chemical compound [Br-].CCCC[P+](CCCC)(CCCC)CCCC RKHXQBLJXBGEKF-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
Definitions
- the present invention relates to N-substituted 9,10-dihydrolysergic acid esters and a process for their preparation.
- the alkyl group is simultaneously introduced into the 1-position of the compound of the general formula II and the group in the 8-position is esterified by the same alkyl group which was introduced into the 1-position.
- R denotes hydrogen or an organic radical which can be hydrolyzed in an alkaline medium.
- 9,10-dihydrplysergic acid esters can also be used for the process according to the invention, in which R denotes any organic radical which is higher than the introduced group R 1 is.
- This organic radical R is replaced by a lower group R 1 by the intermediate alkaline hydrolysis.
- the starting materials of formula II are alkylated by compounds of general formula III in the presence of a phase transfer catalyst.
- This catalyst is an ammonium or phosphonium compound of the general formula Z 4 QA, where Z is the same or different alkyl, cycloalkyl, aryl, arylalkyl or alkylaryl groups with 1-16 C atoms, Q is a quaternary nitrogen or phosphorus atom and A is an anion such as chloride, bromide, iodide, hydrogen sulfate, acetate, tosylate, etc.
- tetrabutylammonium bromide tetrabutylammonium hydrogen sulfate
- triethylbenzylammonium chloride tricaprylylmethylammonium chloride
- tetrabutylphosphonium bromide etc.
- the phase transfer catalyst is used in an amount of 0.1 to 3 moles to 1 mole of 9,10-dihydroloysergic acid.
- the amount of the catalyst within these limits has a great influence on the reaction rate. Since 9,10-dihydrolysergic acid and its derivatives are very sensitive compounds, a rapid course of the reaction is desirable. Therefore, the use of the catalyst in an amount close to the above upper limit is advantageous.
- the water-immiscible inert organic solvent can e.g. Benzene, Toluok, xylene or a saturated hydrocarbon such as pentane, hexane, heptane or cyclohexane.
- the alkaline aqueous phase is a 20-50% aqueous alkali hydroxide solution, e.g. Sodium hydroxide solution.
- the inventive method is carried out at room temperature or moderately elevated temperature.
- the substitution of the 9,10-dihydrolysergic acids in the 8-position is faster than in the 1-position. Therefore, the esters and the N-substituted esters can be isolated from the reaction mixture at the beginning of the reaction. By continuing the reaction, the concentration of the ester is reduced until it completely disappears at the end of the reaction and only the N-substituted ester is obtained.
- the compounds according to the invention are important intermediate compounds for the synthesis of therapeutically highly effective compounds with N-substituted groups in the 1-position.
- the further reactions of the synthesis proceed primarily in the direction of the reduction of the ester group in the 8-position to a primary alcohol group, to which a suitable acid residue, for example 5-bromnicotinic acid, is then bound. Therefore, the simultaneous introduction of the group R 1 in the 1 position and esterification of the carboxy group in the 8 position, which is thereby more accessible for the reduction into the alcohol group, is very advantageous.
- the toluene phase is separated from the water phase and the water phase was extracted 3 times with 200 ml of toluene and 1.66 g (13.22 mmol) of dimethyl sulfate, in each case 20 minutes intensively stirred at 30 ° C.
- the toluene extract is separated from the aqueous solution and then the aqueous solution is extracted twice with 200 ml of toluene and 0.63 g (5 mmol) of dimethyl sulfate.
- the combined toluene extracts are washed with water and evaporated to dryness in vacuo. There are 2.14 g or 71.8% of theory.
- Theor. obtained crystalline 1-methyl-9,10-dihydrolysergic acid methyl ester.
- the compound has the properties given in Example 1.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
N-Substituierte 9,10-Dihydrolysergsäureester der Formel <IMAGE> worin R1 Alkylrests mit 1-5 C-Atomen, Alkenylreste mit 2-5 C-Atomen oder Cycloalkylreste mit 3-5 C-Atomen, R2 Wasserstoff oder Alkoxyreste mit 1-3 C-Atomen und X Wasserstoff oder Halogen bedeuten, wobei die Verbindung, worin R1 Methyl- oder Äthylreste und R2 und X Wasserstoff bedeuten, sowie die Verbindung worin R1 einen Methylrest, R2 einen Methoxyrest und X Wasserstoff bedeuten, ausgenommen sind, als Zwischenverbindugen für die Synthese von therapeutisch hochwirksamen Verbindungen sowie Verfahren zu ihrer Herstellung durch Umsetzung von gegebenenfalls veresterten 9,10-Dihydrolylsergsäuren der allgemeinen Formel <IMAGE> worin R Wasserstoff oder einen in alkalischen Medium hydrolisierbaren organischen Rest bedeutet und X und R2 die vorstehend angegebenen Bedeutungen besitzen, mit einer Verbindung der allgemeinen Formel R1Y (III) worin R1 die unter der Formel I angegebene Bedeutung hat und Y Halogen oder Sulfat bedeutet, in Anwesenheit eines Katalysators zur Phasenübertragung, eines mit Wasser nicht mischbaren inerten organischen Lösungsmittels ind einer alkalischen wässrigen Phase. Diese Verfahren zeichnet sich gegenüber bekannten Verfahren durch eine gute Selektivität, einen einfachen und schellen Reaktionsverlauf, wobei die Reaktion leicht kontrolliert werden kann, die Verwendung von üblichen Lösungsmittel, aus denen das Wasser nicht entfernt werden braucht, sowie vorallem durch Reaktionsbedingungen aus, die ein gefahrloses Arbeiten ermöglichen. Die Verbindungen sind wichtige Zwischenverbindungen zur Synthese von therapeutische hochwirksamen Verbindungen mit N-substituierter Gruppe in der 1-Stellung.N-substituted 9,10-dihydrolysergic esters of the formula <IMAGE> in which R1 is alkyl with 1-5 C atoms, alkenyl with 2-5 C atoms or cycloalkyl with 3-5 C atoms, R2 is hydrogen or alkoxy with 1-3 C atoms and X are hydrogen or halogen, the compound in which R1 is methyl or ethyl and R2 and X are hydrogen, and the compound in which R1 is a methyl radical, R2 is a methoxy radical and X is hydrogen, except as intermediates for the Synthesis of therapeutically highly effective compounds and processes for their preparation by reacting optionally esterified 9,10-dihydrolylsergic acids of the general formula <IMAGE> in which R is hydrogen or an organic radical which can be hydrolyzed in alkaline medium and X and R2 have the meanings indicated above, with a Compound of the general formula R1Y (III) in which R1 has the meaning given under the formula I and Y is halogen or sulfate, in Presence of a phase transfer catalyst, an inert organic solvent immiscible with water and an alkaline aqueous phase. Compared to known processes, this process is distinguished by good selectivity, a simple and rapid course of the reaction, the reaction being easy to control, the use of customary solvents from which the water does not need to be removed, and, above all, by reaction conditions which are safe Enable work. The compounds are important intermediates for the synthesis of therapeutic, highly effective compounds with an N-substituted group in the 1-position.
Description
Die vorliegende Erfindung betrifft N-substituierte 9,10-Dihydrolysergsäureester sowie ein Verfahren zu deren Herstellung.The present invention relates to N-substituted 9,10-dihydrolysergic acid esters and a process for their preparation.
Neue erfindungsgemäße N-substituierte 9,10-Dihydrolysergsäureester der allgemeinen Formel
- R1 Alkylreste mit 1-5 C-Atomen, Alkenylreste mit 2-5 C-Atomen oder Cycloalkylreste mit 3-5 C-Atomen;
- R2 Wasserstoff oder Alkoxyreste mit 1-3 C-Atomen und
- X Wasserstoff oder Halogen bedeuten,
wobei die Verbindung, worin R1 Methyl- oder Äthylresteund R2 und X Wasscrstoff bedeuten, sowie die Verbindung, worin R1 einen Methylrest, R2 einen Methoxyrest und X Wasserstoff bedeuten, ausgenommen sind,
sind wichtige Zwischenverbindungen für die Synthese von therapeutisch hochwirksamen Verbindungen.New N-substituted 9,10-dihydrolysergic esters of the general formula according to the invention
- R 1 alkyl radicals with 1-5 C atoms, alkenyl radicals with 2-5 C atoms or cycloalkyl radicals with 3-5 C atoms;
- R 2 is hydrogen or alkoxy radicals with 1-3 C atoms and
- X is hydrogen or halogen,
with the exception of the compound in which R 1 is methyl or ethyl and R 2 and X are hydrogen, and the compound in which R 1 is methyl, R 2 is methoxy and X is hydrogen,
are important intermediates for the synthesis of therapeutically highly effective compounds.
Das bisher bekannte Verfahren der N-Alkylierung von Lysergsäuren oder anderen Verbindungen dieser Basisstruktur beruht auf der Metallisierung von Indolstickstoff mit Kalium oder Lithium in flüssigem Ammoniak bei -50°C und anschliessender Einführung der Alkylgruppe. Gemäß diesem Verfahren wird die Alkylgruppe nur in die 1-Stelluna eingeführt, Da die Reaktion niaht Lesonders selektiv ist, wird sie, insbesondere beim notwendigen Überschuss von Alkylhalogenid, auch durch die Substitution des aktivierten Wasserstoffs am Chiralitätszentrum 8 mit einer Alkylgruppe begleitet, so dass die Ausbeute an N-Alkylverbindung geringer wird (F. Troxler und A. Hofmann, Helv. chim. Acta 40, 1957, 1721). Die Arbeit unter den angegebenen Reaktionsbedingungen ist aufwendig, es sind wasserfreie Lösungsmittel erforderlich und unter ungünstigen Bedingungen kann es auch zu Explosionen kommen. Das Reaktionsprodukt muss durch Säulenchromatographie gereinigt werden.The previously known process of N-alkylation of lysergic acids or other compounds of this basic structure is based on the metallization of indole nitrogen with potassium or lithium in liquid ammonia at -50 ° C. and the subsequent introduction of the alkyl group. According to this The alkyl group is only introduced into the 1-stelluna, since the reaction is not particularly selective, especially when the excess of alkyl halide is necessary, it is also accompanied by the substitution of the activated hydrogen at the chiral center 8 with an alkyl group, so that the yield increases N-alkyl compound decreases (F. Troxler and A. Hofmann, Helv. Chim. Acta 40, 1957, 1721). Working under the specified reaction conditions is complex, anhydrous solvents are required and, under unfavorable conditions, explosions can also occur. The reaction product has to be purified by column chromatography.
Das erfindungsgemässe Verfahren zur Herstellung von N-alkylierten 9,10-dihydrolysergsäureestern der allgemeinen Formel I ist dadurch gekennzeichnet, dass die gegebenenfalls veresterten 9,10-Dihydroloysergsäureester der allgemeinen Formel
- R Wassarstoff oder einen in alkalischem Medium hydrqlisierbaren organischen Rest be- deutet, und
- X und R2 die unter Formel I angegebene Bedeutung haben,
mit einer Verbindung der allgemeinen Formel worin - R1 die unter Formel I angegebene Bedeutung hat, und
- Y Halogen oder Sulfat bedeutet,
in Anwesenheit eines Katalysators zur Pha- ,senübertragung, eines,mit Wasser nicht mischbaren inerten organischen Lösungsmittels und einer alkalischen wässerigen Phase umgesetzt werden.The process according to the invention for the preparation of N-alkylated 9,10-dihydrolysergic esters of the general formula I is characterized in that the optionally esterified 9,10-dihydrolysergic esters of the general formula
- R is hydrogen or an organic radical which can be hydrolyzed in an alkaline medium, and
- X and R 2 have the meaning given under formula I,
with a compound of the general formula wherein - R 1 has the meaning given under formula I, and
- Y is halogen or sulfate,
in the presence of a catalyst for phase transfer, a water-immiscible inert organic solvent and an alkaline aqueous phase.
Nach dem erfindungsgemässen Verfahren wird gleichzeitig in die 1-Stellung der Verbindung der allgemeinen Formel II die Alkylgruppe eingeführt und die Gruppe in der 8-Stellung wird durch dieselbe Alkylgruppe, die in die 1-Lage eingeführt wurde, verestert.In the process according to the invention, the alkyl group is simultaneously introduced into the 1-position of the compound of the general formula II and the group in the 8-position is esterified by the same alkyl group which was introduced into the 1-position.
In der Verbindung der allgemeinen Formel II bedeutet R Wasserstoff oder einen in alkalischem Medium hydrolysierbaren organischen Rest. Deswegen können für das erfindungsgemässe Verfahren auch dee 9,10-Dihydrplysergsäureester verwendet werden, worin R irgend einen organischen Rest bedeutet, der höher als die eingeführte Gruppe R1 ist. Dieser organische Rest R wird durch die intermediäre alkalische Hydrolyse durch eine niedrigere Gruppe R1 ersetzt.In the compound of the general formula II, R denotes hydrogen or an organic radical which can be hydrolyzed in an alkaline medium. For this reason, 9,10-dihydrplysergic acid esters can also be used for the process according to the invention, in which R denotes any organic radical which is higher than the introduced group R 1 is. This organic radical R is replaced by a lower group R 1 by the intermediate alkaline hydrolysis.
Die Verbindungen deralicemeinen Formeln II und III sind bekannt und in der Literatur beschrieben oder können durch an sich bekannte Verfahren hergestellt Werden.The compounds of all my formulas II and III are known and described in the literature or can be prepared by processes known per se.
Die Ausgangsstoffe der Formel II werden durch Verbindungen der allgemeinen Formel III in Anwesenheit einesr Katalysators zur Phasenübertragung alkyliert. Dieser Katalysator ist eine Ammonium- oder Phosphoniumverbindung der allgemeinen Formel Z4QA, worin Z gleiche oder verschiedene Alkyl-, Cycloalkyl-, Aryl-, Arylalkyl- oder Alkylarylgruppen mit 1-16 C-Atomen, Q ein quaternäres Stickstoff- oder Phosphoratom und A ein Anion, wie Chlorid, Bromid, Jodid, Hydrogensulfat, Acetat, Tosylat usw., bedeuten. Als Katalysator zur Phasenübertragung können also z.B. Tetrabutylammoniumbromid, Tetrabutylammoniumhydrogensulfat, Triäthylbenzylammoniumchlorid, Tricaprylylmethylammoniumchlorid, Tetrabutylphosphoniumbromid usw. eingesetzt werden.The starting materials of formula II are alkylated by compounds of general formula III in the presence of a phase transfer catalyst. This catalyst is an ammonium or phosphonium compound of the general formula Z 4 QA, where Z is the same or different alkyl, cycloalkyl, aryl, arylalkyl or alkylaryl groups with 1-16 C atoms, Q is a quaternary nitrogen or phosphorus atom and A is an anion such as chloride, bromide, iodide, hydrogen sulfate, acetate, tosylate, etc. Thus, for example, tetrabutylammonium bromide, tetrabutylammonium hydrogen sulfate, triethylbenzylammonium chloride, tricaprylylmethylammonium chloride, tetrabutylphosphonium bromide, etc. can be used as the catalyst for phase transfer.
Der Katalysator zur Phasenübertragung wird in einer Menge von 0,1 bis 3 Mol auf 1 Mol 9,10-Dihydroloysergsäure eingesetzt. Die Menge des Katalysators in diesen Grenzen beeinflusst sehr die Reaktionsgeschwindigkeit.. Da 9,10-Dihydrolysergsäure und ihre Derivate sehr empfindliche Verbindungen sind, ist ein schneller Reaktionsverlauf erwünscht. Deswegen ist die Verwendung des Katalysators in einer Menge vorteilhaft, die nahe an der angeführten oberen Grenze liegt.The phase transfer catalyst is used in an amount of 0.1 to 3 moles to 1 mole of 9,10-dihydroloysergic acid. The amount of the catalyst within these limits has a great influence on the reaction rate. Since 9,10-dihydrolysergic acid and its derivatives are very sensitive compounds, a rapid course of the reaction is desirable. Therefore, the use of the catalyst in an amount close to the above upper limit is advantageous.
Das mit Wasser nicht mischbare inerte organische Lösungsmittel kann z.B. Benzol, To- luok,Xylol oder ein gesättigter Kohlenwasserstoff, wie Pentan, Hexan, Heptan oder Cyclohexan, sein.The water-immiscible inert organic solvent can e.g. Benzene, Toluok, xylene or a saturated hydrocarbon such as pentane, hexane, heptane or cyclohexane.
Die alkalische wässerige Phase ist eine 20-50 %ige wässerige Alkalihydroxydlösung, z.B. Natriümhydroxydlösung.The alkaline aqueous phase is a 20-50% aqueous alkali hydroxide solution, e.g. Sodium hydroxide solution.
Das erfindungsgemässe Verfahren wird bei Raumtemperatur oder mässig erhöhter Temperatur durchgeführt.The inventive method is carried out at room temperature or moderately elevated temperature.
Die Substitution der 9,10-Dihydrolysergsäuren in der 8-Stellung verläuft schneller als in der 1-Stellung. Deswegen können am Anfang der Reaktion aus dem Reaktionsgemisch der Ester und der N-substituierte Ester isoliert werden. Durch die Weiterführung der Reaktion wird die Konzentration des Esters vermindert, bis sie am Ende der Reaktion vollkommen verschwindet und nur der N-substituierte Ester erhalten wird. Deswegen kann bei der Einführung einer Alkyl- bzw. Alkenyl-und Cycloalkylgruppe in einen 9,10-Dihydrolysergsäurealkyl- bzw. -alkenyl und -cycloalkylester in hoher Ausbeute ein 1-(Alkyl oder Alkenyl oder Cycloalkyl)-9,10-dihydrolysergsäu- realkyl-, -alkenyl- oder -cycloalkylester erhalten werden.The substitution of the 9,10-dihydrolysergic acids in the 8-position is faster than in the 1-position. Therefore, the esters and the N-substituted esters can be isolated from the reaction mixture at the beginning of the reaction. By continuing the reaction, the concentration of the ester is reduced until it completely disappears at the end of the reaction and only the N-substituted ester is obtained. For this reason, when an alkyl or alkenyl and cycloalkyl group is introduced into a 9,10-dihydrolysergic acid alkyl or alkenyl and cycloalkyl ester, a 1- (alkyl or alkenyl or cycloalkyl) -9,10-dihydrolyseric acid alkyl can be obtained in high yield -, -Alkenyl or -cycloalkyl esters can be obtained.
Die Vorteile des erfindungsgemässen Verfahrens gegenüber dem bekannten Verfahren sind gute Selektivität, einfacher und schneller Reaktionsverlauf, wobei die Reaktion leicht kontrolliert wird, Verwendung von üblichen Lösungsmitteln, aus welchen das Wasser nicht entfernt zu werden braucht, vor allem jedoch die Reaktionsbedingungen, die eine fahrlose Arbeit ermöglichen.The advantages of the method according to the invention over the known method are good selectivity, simple and fast reaction course, the reaction being easily controlled, use of conventional solvents from which the water cannot be removed needs, but above all the reaction conditions that make driving possible.
Die erfindungsgemässen Verbindungen sind wichtige Zwischenverbindungen zur Synthese von therapeutisch hochwirksamen Verbindungen mit N-substituierter Gruppen in 1-Stellung. Die weiteren Umsetzungen der Synthese verlaufen vor allem in der Richtung der Reduktion der Estergruppe in der 8-Stellung zu einer primären Alkoholgruppe, auf die dann ein geeigneter Säurerest, z.B. der 5-Bromnicotinsäure, gebunden wird. Deswegen ist die gleichzeitige Einführung der Gruppe R1 in die 1-Stellung und Veresterung der Carboxygruppe in der 8-Stellung, die dadurch für die Reduktion in die Alkoholgruppe zugänglicher wird, sehr vorteilhaft.The compounds according to the invention are important intermediate compounds for the synthesis of therapeutically highly effective compounds with N-substituted groups in the 1-position. The further reactions of the synthesis proceed primarily in the direction of the reduction of the ester group in the 8-position to a primary alcohol group, to which a suitable acid residue, for example 5-bromnicotinic acid, is then bound. Therefore, the simultaneous introduction of the group R 1 in the 1 position and esterification of the carboxy group in the 8 position, which is thereby more accessible for the reduction into the alcohol group, is very advantageous.
2,7 g (10 mMol) 9,10-Dihydrolysergsäure und 7 g (20 mMol) Tetrabutylammoniumhydrogensulfat werden in 200 ml 45 %igem Natriumhydroxyd suspendiert. Eine Lösung von 4,2 g (.30 mMol) Methyljodid in 300 ml Benzol wird zugegeben und 1 Stunde intensiv.gerührt. Organische Phase wird dann getrennt und die wässerige Phase in gleicher Weise noch 2 mal mit je 150 ml Benzol, das 2,1 g (15 mMol) Methyljodid enthält, extrahiert. Die Benzolextrakte werden vereinigt, mit Wasser bis zur neutralen Reaktion gewaschen und das Lösungsmittel wird eingedampft. Es werden 2,62 g bzw. 88 % d. Theor. reinen, kristallinen 1-Methyl-9,10-di- hydolysergsäuremethylester mit Schmp. von 116-119°C und einer spezifischen Drehung von
In ein aus 200 ml 50 %igem Natriumhydroxyd, 7 g (20 mMol) Tetrabutylammoniumhydrogensulfat, 2,8 g (20 mMol) Methyljodid und 300 ml Benzol bestehendes Zweiphasensystem werden unter intensivem Rähren 2,84 g (10 mMol) 9,10-Dihydrolysergsäuremethylester zugegeben. Es wird 30 Minuten gerührt und anschliessend werden die Phasen getrennt. Der wässerigen Phase werden 200 ml Benzol mit 2,1 g (15 mMol) Methyljodid zugegeben und 30 Minuten weitergerührt. Dann werden beide Phasen getrennt und die wässerige Phase noch 2 mal mit je 150 ml Benzol extrahiert. Alle vier Benzolextrakte werden mit Wasser bis zur neutralen Reaktion gewaschen und eingedampft. Es werden 2,7 g bzw. 91 % d. Theor. reinen, kristallinen 1-Methyl-9,10-dihydrolysergsäuremethylester erhalten. Die Verbindung hat die gleichen Eigenschaften wie im Beispiel 1.In a two-phase system consisting of 200 ml of 50% sodium hydroxide, 7 g (20 mmol) of tetrabutylammonium hydrogen sulfate, 2.8 g (20 mmol) of methyl iodide and 300 ml of benzene, 2.84 g (10 mmol) of 9,10-dihydrolysergic acid methyl ester are stirred intensively admitted. The mixture is stirred for 30 minutes and then the phases are separated. 200 ml of benzene with 2.1 g (15 mmol) of methyl iodide are added to the aqueous phase and stirring is continued for 30 minutes. Then both phases are separated and the aqueous phase extracted twice with 150 ml of benzene. All four benzene extracts are washed with water until neutral and evaporated. There are 2.7 g or 91% of theory. Theor. obtained pure, crystalline 1-methyl-9,10-dihydrolysergic acid methyl ester. The compound has the same properties as in Example 1.
2,7 g (10 mMol) 9,10-Dihydrolysergsäure und 6,44 g (20 mMol) Tetrabutylammoniumbromid werden in 200 ml 45 %igem Natriumhydroxyd suspendiert. Es wird eine Lösung von 3,78 g (30 mMol) Dimethyl-sulfat in 300 ml Benzol zugegeben und 1 Stunde intensiv gerührt. Dann wird die organische Phase getrennt und die wässerige Phase in gleicher Weise noch 2 mal mit je 150 ml Benzol und 2,1 g (15 mMol) Methyljodid extrahiert. Die Benzolextrakte werden vereinigt, mit Wasser bis zur neu- tralen Reaktion gewaschen und in Vakuum eingedampft. Es werden 2,36 g bzw. 82,6 % d. Theor. reinen, kristallinen 1-Methyl-9,10-dihydroly- sergsäuremethylester erhalten. Die Verbindung hat die gleichen Eigenschaften wie im Beispiel 1.2.7 g (10 mmol) of 9,10-dihydrolysergic acid and 6.44 g (20 mmol) of tetrabutylammonium bromide are suspended in 200 ml of 45% sodium hydroxide. A solution of 3.78 g (30 mmol) of dimethyl sulfate in 300 ml of benzene is added and the mixture is stirred intensively for 1 hour. The organic phase is then separated and the aqueous phase is extracted in the same way twice with 150 ml of benzene and 2.1 g (15 mmol) of methyl iodide. The benzene extracts are combined, washed with water until neutral and evaporated in vacuo. 2.36 g or 82.6% of theory. Theor. obtained pure, crystalline 1-methyl-9,10-dihydrolysergic acid methyl ester. The compound has the same properties as in Example 1.
2,7 g (10 mMol) 9,10-Dihydrolysergsäure und 7 g (20 mMol) Tetrabutylammoniumhydrogensul- fat werden in 200 ml 45 %igem Natriumhydroxyd suspendiert und eine Lösung von 4,62 g (30 mMol) Diäthylsulfat in 300 ml Toluol wird zugegeben. Bei Raumtemperatur wird 8 Stunden intensiv gerührt. Dann wird die organische Phase getrennt und die wässerige Phase in gleicher Weise noch 4 Stunden mit 300 ml Toluol und 1,54 g (10 mMol) Diäthylsulfat extrahiert. Die Toluolextrakte werden vereinigt, mit Wasser bis zur neutralen Reaktion gewaschen und in Vakuum eingedampft. Es werden 2,15 g bzw. 68,7 % d. Theor. reinen, kristallinen 1-Äthyl-9,10-dihydrolysergsäureäthyl- ester mit einem Schmp. von 80-82°C und spezifischer Drehung
2,7 g (10 mMol) 9,10-Dihydrolysergsäure und 7 g ,(20 mMol) Tetrabutylammoniumhydrogensulfat werden in 200 ml 45 %igem Natriumhydroxyd suspendiert, eine Lösung von 4,85 g (40 mMol) Allylbromid in 300 ml Benzol wird zugegeben und 2 Stunden-intensiv gerührt. Dann werden die Phasen getrennt und die wässerige Phase in gleicher Weise noch 2 mal mit je 200 ml Benzol und 2,42 g (20 mMol) Allylbromid extrahiert. Die Benzolextrakte werden vereinigt, mit Wasser bis zur neutralen Reaktion gewaschen und in Vakuum eingedampft. Es werden 2,3 g bzw. 66 % d. Theor. 1-Allyl-9,10-dihydrolysergsäureallylester in der Form eines farblosen Harzes mit spezifischer Drehung von
Ein Gemisch aus 4,5 g (13,22 mMol) 10α-Methoxy-lumilysergsäuremethylester, 8,67 g (26,44 mMol) Tetrabutylammoniumhydrogensulfat, 200 ml 45 %igem Natriumhydroxyd, 300 ml Toluol und 3,33 g (26,44 mMol) Dimethylsulfat wird 20 Minuten bei 30°C intensiv gerührt. Dann wird die Toluolphase von der Wasserphase getrennt und die Wasserphase-noch 3 mal mit je 200 ml Toluol und 1,66 g (13,22 mMol) Dimethylsulfat extrahiert, wobei jeweils 20 Minuten intensiv bei 30°C gerührt wird. Die vereinigten Toluolextrakte werden mit Wasser gevaschen und in Vakuum eingedampft. Es werden 3,8 g 1-Methyl-10α-methoxy- in der Form eines farblosen Harzes mit der spezifischen Drehung
In eine Suspension von 40 ml 45 %igem Natriumhydroxid, 4,87 g (14,3 mMol) Tetrabutylammoniumhydrogensulfat, 250 ml Benzol und 3 g (21,5 mMol) Methyljodid werden unter invensivem Rühren bei 35°C 2,6 g (7,16 mMol) 2-Brom-9,10-dihydrolysergsäuremethylester in 65 ml Benzol zugegeben. Die Lösung wird 30 Minuten gerührt und anschliessehd wird die organische Phase von der wässerigen Phase getrennt. Die wässerige Phase wird hoch 2 mal mit je 150 ml Benzol und 1,5 g (10,7 mMol) Methyljodid extrahiert. Die vereinigten Benzolextrakte werden mit Wasser gewaschen und in Vakuum eingedampft. Der Trockenrückstand wird aus Methanol kristallisiert. Es werden 2,42 g bzw. 90 % d. Theor. kristallinen 1-Methyl-2-brom-9,10-dihydrolysergsäuremethyl- ester mit Schmp. 167-168°C und der spezifischen Drehung
In eine Suspension aus 80 ml 45 %igem Natriumhydroxyd, 3,5 g (10 mMol) Tetrabutylammoniumhydrogensulfat, 200 ml Cyclohexan und 3,51 g (22,5 mMol) Äthyljodid werden unter Rühren 1,45 g (5mMol) 9,10-Dihydrolysergsäureäthyl- ester zugegeben. Es wird 18 Stunden intensiv bei 60°C gerührt. Nach der Trennung beider Phasen wird die wässerige Phase noch einmal mit 150 ml Cyclohexan und 1,56 g (10 mMol) Äthyljodid extra- hiert. Die Cyclohexanfraktionen werden vereinigt, mit Wasser gewaschen und eingedampft. Es werden 1,22 g bzw. 80% d. Theor. 1-Äthyl-9,10-dihydroly- sergsäüreäthylester mit einem Schmp. von 80-83°C und einer spezifischen Drehung
In ein Zweiphasensysten bestehend aus 200 ml 45 %igem Natriumhydroxyd, 7 g (20 mMol) Tetrabutylammoniumhydrogensulfat, 200 ml Toluol und 2,52 g (20 mMol) Dimethylsulfat, wird unter intensiver Rühren eine Lösung von 3,16 g (10 mMol) 9,10-Dihydrolysergsäure-2'-fluoräthylester in 100 ml Toluol zugegeben und 2 Stunden gerührt. Der Toluolextrakt wird von der wässerigen Lösung getrennt und dann wird die wässerige Lösung noch 2 mal mit je 200 ml Toluol und 0,63 g (5 mMol) Dimethylsulfat extrahiert. Die vereinigten Toluolextrakte werden mit Wasser gewaschen und in Väkuum bis zur Trockne eingedampft. Es werden 2,14 g bzw. 71,8 % d. Theor. kristallinen 1-Methyl-9,10-di- hydrolysergsäuremethylester erhalten. Die Verbindung hat die im Beispiel 1 angegebenen Eigenschaften.In a two-phase system consisting of 200 ml of 45% sodium hydroxide, 7 g (20 mmol) of tetrabutylammonium hydrogen sulfate, 200 ml of toluene and 2.52 g (20 mmol) of dimethyl sulfate, a solution of 3.16 g (10 mmol) 9 is stirred , 10-Dihydrolysergic acid 2'-fluoroethyl ester in 100 ml of toluene and stirred for 2 hours. The toluene extract is separated from the aqueous solution and then the aqueous solution is extracted twice with 200 ml of toluene and 0.63 g (5 mmol) of dimethyl sulfate. The combined toluene extracts are washed with water and evaporated to dryness in vacuo. There are 2.14 g or 71.8% of theory. Theor. obtained crystalline 1-methyl-9,10-dihydrolysergic acid methyl ester. The compound has the properties given in Example 1.
Claims (2)
mit einer Verbindung der allgemeinen Formel
in Anwesenheit eines Katalysators zur Phasenübertragung, eines mit Wasser nicht mischbaren inerten organischen Lösungsmittels und einer alkalischen wässerigen Phase umgesetzt werden.2. Process for the preparation of N-substituted 9,10-dihydrolysergic acid esters of the general formula
with a compound of the general formula
in the presence of a phase transfer catalyst, a water-immiscible inert organic solvent and an alkaline aqueous phase.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| YU1819/77 | 1977-07-21 | ||
| YU1819/77A YU40004B (en) | 1977-07-21 | 1977-07-21 | Praocess for preparing n-substituted esters of 9,10-dihydrlysergic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0000533A1 true EP0000533A1 (en) | 1979-02-07 |
| EP0000533B1 EP0000533B1 (en) | 1981-08-05 |
Family
ID=25555705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP78100419A Expired EP0000533B1 (en) | 1977-07-21 | 1978-07-18 | N-substituted 9,10-dihydrolysergic acid esters and a method for their preparation |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4230859A (en) |
| EP (1) | EP0000533B1 (en) |
| JP (1) | JPS5436296A (en) |
| AT (1) | AT363195B (en) |
| CS (1) | CS216231B2 (en) |
| DE (1) | DE2860896D1 (en) |
| ES (1) | ES471716A1 (en) |
| FI (1) | FI64369C (en) |
| PT (1) | PT68278A (en) |
| SU (1) | SU784775A3 (en) |
| YU (1) | YU40004B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0208622A1 (en) * | 1985-07-11 | 1987-01-14 | Rhone-Poulenc Sante | Process for the preparation of N-methyl derivatives of ergoline |
| FR2584721A1 (en) * | 1985-07-11 | 1987-01-16 | Rhone Poulenc Sante | PROCESS FOR PREPARING N-METHYL DERIVATIVES OF METHYL DIHYDROLYSERGATE OR METHYL METHOXYLUMILYSERGATE |
| EP0218433A1 (en) * | 1985-10-01 | 1987-04-15 | Eli Lilly And Company | Selective method for blocking 5HT2 receptors |
| EP0219256A1 (en) * | 1985-10-01 | 1987-04-22 | Eli Lilly And Company | N-Alkylation of dihydrolysergic acid |
| EP0291270A3 (en) * | 1987-05-11 | 1989-12-06 | Eli Lilly And Company | Improvements in or relating to ergoline derivatives |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4563461A (en) * | 1983-03-10 | 1986-01-07 | Eli Lilly And Company | Selective method for blocking 5HT2 receptors |
| US4772709A (en) * | 1985-10-01 | 1988-09-20 | Eli Lilly And Company | Process of making ketoalkanol esters of dihydrolysergic acid |
| US4845224A (en) * | 1985-10-01 | 1989-07-04 | Eli Lilly And Company | Cycloalkanol esters of dihydrolysergic acid having peripheral serotonin antagonist properties |
| US4810710A (en) * | 1985-10-01 | 1989-03-07 | Eli Lilly And Company | 4-hydroxycyclohexyl 1-isopropyl-9,10-dihydro-lysergate for the treatment of migraine |
| US4714704A (en) * | 1985-10-01 | 1987-12-22 | Eli Lilly And Company | Alkoxy cycloalkanol esters of dihydrolysergic acid useful as 5HT receptor antagonists |
| US4847261A (en) * | 1985-10-01 | 1989-07-11 | Eli Lilly And Company | Alkoxy cycloalkanol esters of dihydrolysergic acid having peripheral serotonin antagonists properties |
| US4713385A (en) * | 1985-10-01 | 1987-12-15 | Eli Lilly And Company | Alkoxy and dialkoxyalkyl esters of dihydrolysergic acid and related compounds useful as 5HT receptor antagonists |
| US4762842A (en) * | 1985-10-01 | 1988-08-09 | Eli Lilly And Company | Selective method for blocking 5HT2 receptors |
| US4968802A (en) * | 1985-10-01 | 1990-11-06 | Eli Lilly And Company | Process of making alkoxy cycloalkanol esters of dihydrolysergic acid |
| US4939258A (en) * | 1985-10-01 | 1990-07-03 | Eli Lilly And Company | Cycloalkanol esters of dihydrolysergic acid |
| US4820713A (en) * | 1985-10-01 | 1989-04-11 | Eli Lilly And Company | Ketoalkanol esters of dihydrolysergic acid useful as 5HT receptor antagonists |
| US4683236A (en) * | 1985-10-01 | 1987-07-28 | Eli Lilly And Company | Cycloalkanol esters of dihydrolysergic acid useful as 5Ht2 receptor antagonists |
| US4906639A (en) * | 1985-10-01 | 1990-03-06 | Eli Lilly And Company | Cycloalkanol esters of dihydrolysergic acid |
| US4683237A (en) * | 1985-12-20 | 1987-07-28 | Eli Lilly And Company | Fluoroalkyl esters of dihydrolysergic acid useful as 5HT2 receptor antagonists |
| US4704396A (en) * | 1985-12-20 | 1987-11-03 | Eli Lilly And Company | Phenacyl esters of 1-substituted-6-(substituted and unsubstituted) dihydrolysergic acids useful as 5HT receptor antagonists |
| US4704395A (en) * | 1985-12-20 | 1987-11-03 | Eli Lilly And Company | Cyclic ether esters of 2-substituted-6-(substituted and unsubstituted) dihydrolysergic acid useful as 5HT receptor antagonists |
| US4835159A (en) * | 1987-05-11 | 1989-05-30 | Eli Lilly And Company | Ergoline esters useful as serotonin antagonists |
| US4981859A (en) * | 1987-06-15 | 1991-01-01 | Cycloalkylamides of (8 beta )-1-alkyl-6-(substituted)ergolines | |
| US4931447A (en) * | 1987-06-15 | 1990-06-05 | Eli Lilly And Company | Cycloalkylamides of (8β)-1-alkyl-6-(substituted) ergolines |
| JPH01106511U (en) * | 1988-01-02 | 1989-07-18 | ||
| JPH02125915U (en) * | 1989-03-29 | 1990-10-17 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1175276A (en) * | 1956-05-18 | 1959-03-23 | Sandoz Ag | New derivatives of the lysergic acid series and their preparation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA631701A (en) * | 1961-11-28 | Sandoz A.G. | Compounds of the lysergic acid series alkylated at the indol nitrogen atom | |
| CH344731A (en) * | 1956-05-18 | 1960-02-29 | Sandoz Ag | Process for the production of new derivatives of the lysergic acid series alkylated on the indole nitrogen |
| US3228943A (en) * | 1962-06-11 | 1966-01-11 | Lumilysergol derivatives | |
| US3232942A (en) * | 1964-06-02 | 1966-02-01 | Sandoz Ltd | 1-substituted (+)-lysergol |
| GB1298277A (en) * | 1969-04-18 | 1972-11-29 | Sandoz Ltd | Preparation of ergot peptide alkaloids |
| US3879554A (en) * | 1970-03-20 | 1975-04-22 | Farmaceutici Italia | Use of 1,6-dimethyl-8-{62 -(5-bromonicotinoyloxymethyl)-10 {60 -methoxyergoline in treating cerebral and peripheral metabolic vascular disorders |
| NL159384B (en) * | 1971-03-13 | 1979-02-15 | Farmaceutici Italia | PROCEDURE FOR PREPARING A MEDICINAL PRODUCT WITH AN ADRENOLYTIC ACTIVITY, AS WELL AS A PROCEDURE FOR PREPARING AN ESTER OF 1-METHYL-10-METHOXYLUMILYSERGOL. |
| DE2330912C3 (en) * | 1972-06-22 | 1979-01-11 | Societa Farmaceutici Italia S.P.A., Mailand (Italien) | Process for the preparation of bromergoline compounds |
-
1977
- 1977-07-21 YU YU1819/77A patent/YU40004B/en unknown
-
1978
- 1978-06-29 FI FI782081A patent/FI64369C/en not_active IP Right Cessation
- 1978-07-06 AT AT0490078A patent/AT363195B/en not_active IP Right Cessation
- 1978-07-07 US US05/922,692 patent/US4230859A/en not_active Expired - Lifetime
- 1978-07-12 PT PT68278A patent/PT68278A/en unknown
- 1978-07-14 ES ES471716A patent/ES471716A1/en not_active Expired
- 1978-07-18 DE DE7878100419T patent/DE2860896D1/en not_active Expired
- 1978-07-18 EP EP78100419A patent/EP0000533B1/en not_active Expired
- 1978-07-18 CS CS784790A patent/CS216231B2/en unknown
- 1978-07-20 SU SU782637592A patent/SU784775A3/en active
- 1978-07-21 JP JP8850978A patent/JPS5436296A/en active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1175276A (en) * | 1956-05-18 | 1959-03-23 | Sandoz Ag | New derivatives of the lysergic acid series and their preparation |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0208622A1 (en) * | 1985-07-11 | 1987-01-14 | Rhone-Poulenc Sante | Process for the preparation of N-methyl derivatives of ergoline |
| FR2584721A1 (en) * | 1985-07-11 | 1987-01-16 | Rhone Poulenc Sante | PROCESS FOR PREPARING N-METHYL DERIVATIVES OF METHYL DIHYDROLYSERGATE OR METHYL METHOXYLUMILYSERGATE |
| FR2584720A1 (en) * | 1985-07-11 | 1987-01-16 | Rhone Poulenc Sante | PROCESS FOR THE PREPARATION OF N-METHYL DERIVATIVES OF ERGOLINE |
| EP0211728A1 (en) * | 1985-07-11 | 1987-02-25 | Rhone-Poulenc Sante | Process for the preparation of the N-methyl derivatives of the methyl ester of dihydrolysergic acid or of the methyl ester of methoxylumilysergic acid |
| US4739061A (en) * | 1985-07-11 | 1988-04-19 | Rhone-Poulenc Sante | Process for preparing n-methyl derivatives of methyl dihydrolysergate and methyl methoxylumilysergate |
| US4754037A (en) * | 1985-07-11 | 1988-06-28 | Rhone-Poulenc Sante | Process for preparing N-methyl derivatives of ergoline |
| EP0218433A1 (en) * | 1985-10-01 | 1987-04-15 | Eli Lilly And Company | Selective method for blocking 5HT2 receptors |
| EP0219256A1 (en) * | 1985-10-01 | 1987-04-22 | Eli Lilly And Company | N-Alkylation of dihydrolysergic acid |
| EP0291270A3 (en) * | 1987-05-11 | 1989-12-06 | Eli Lilly And Company | Improvements in or relating to ergoline derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2860896D1 (en) | 1981-11-05 |
| ATA490078A (en) | 1980-12-15 |
| FI64369C (en) | 1983-11-10 |
| US4230859A (en) | 1980-10-28 |
| CS216231B2 (en) | 1982-10-29 |
| SU784775A3 (en) | 1980-11-30 |
| AT363195B (en) | 1981-07-10 |
| EP0000533B1 (en) | 1981-08-05 |
| PT68278A (en) | 1978-08-01 |
| JPS5436296A (en) | 1979-03-16 |
| YU181977A (en) | 1983-01-21 |
| FI782081A7 (en) | 1979-01-22 |
| FI64369B (en) | 1983-07-29 |
| YU40004B (en) | 1985-06-30 |
| JPS5648512B2 (en) | 1981-11-16 |
| ES471716A1 (en) | 1979-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0000533B1 (en) | N-substituted 9,10-dihydrolysergic acid esters and a method for their preparation | |
| CH617442A5 (en) | ||
| EP0086324B1 (en) | Process for preparing ascorbic acid | |
| DE2661094C2 (en) | ||
| DE69707860T2 (en) | METHOD FOR PRODUCING TETRAHYDROINDOLIZINES | |
| DE2318001A1 (en) | NEW DIENIC SULPHONES | |
| DD201592A5 (en) | PROCESS FOR THE PREPARATION OF NEW INDOLOCHINOLISINESTER DERIVATIVES | |
| DE2752533B2 (en) | Process for the preparation of 10 a -Methoxydttiydrolysergol-S'-bromnocotinsäureester | |
| CH642658A5 (en) | RACEMIC OR OPTICALLY ACTIVE OXIMINO-E-HOMO-EBURNAN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF. | |
| DE2354327C3 (en) | 2-Amino-1,23> 4-tetrahydronaphthalene derivatives, processes for their preparation and processes for the preparation of 6,7-benzomorphans starting from those | |
| DE2521088A1 (en) | DITERPENIC ANILIDES AND METHOD FOR MANUFACTURING THEREOF | |
| DE2065698A1 (en) | PROCESS FOR THE PREPARATION OF 2ISOPROPYL-6-METHYL-4 (3H) -PYRIMIDONE | |
| DE1643014C3 (en) | Process for the production of cardenolides | |
| EP0003484B1 (en) | Process for the preparation of chromane derivatives | |
| DE2256866C3 (en) | Process for the preparation of 17 alpha- or 17beta-hydroxy compounds of the 20-ketopregnane or -17alpha-pregnane series | |
| DE2331044A1 (en) | DIPHENYLMETHANE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | |
| DE2516544A1 (en) | PROCESS FOR PRODUCING TRANS-DECALIN DERIVATIVES | |
| DE2533899C3 (en) | Process for the preparation of steryl-β-glucoside esters | |
| DE2628469B2 (en) | Process for the preparation of γ-amino alcohols | |
| DE2705874C2 (en) | Process for the preparation of phloroglucinol and phloroglucinol derivatives | |
| DE2243112C3 (en) | Process for the preparation of substituted aromatic compounds nitrated in the side chain | |
| DE2517770C3 (en) | Process for the production of | |
| DE68915213T2 (en) | Process for the preparation of vitamin A or its carboxylic acid esters. | |
| DE1643587C3 (en) | Process for the production of 13 alkylgon 5 (10> en 3 beta oils | |
| DE2238586C3 (en) | Process for the production of A16-17 ethinyl steroids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Designated state(s): BE CH DE FR GB SE |
|
| 17P | Request for examination filed | ||
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Designated state(s): BE CH DE FR GB SE |
|
| REF | Corresponds to: |
Ref document number: 2860896 Country of ref document: DE Date of ref document: 19811105 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19840630 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19840710 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19840719 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19840927 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19840930 Year of fee payment: 7 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19860719 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19860731 Ref country code: BE Effective date: 19860731 |
|
| BERE | Be: lapsed |
Owner name: LEK TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV N. Effective date: 19860731 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19870331 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19870401 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881117 |
|
| EUG | Se: european patent has lapsed |
Ref document number: 78100419.7 Effective date: 19870518 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |